Premas Life Sciences and Sphere Bio Join Forces to Boost Single-Cell Research in South Asia
India PR Distribution
Delhi [India], May 6: Premas Life Sciences Pvt. Ltd. (PLS), a pioneering enabler of life science innovations in India, has announced a strategic collaboration with Sphere Bio , a worldwide pioneer in picodroplet-based microfluidics for functional single-cell analysis. This collaboration marks a substantial advancement in delivering revolutionary, next-generation platforms to scientists and researchers across India and Bangladesh. Both entities share a common objective: equipping the biopharmaceutical, biotechnology, and academic sectors with advanced tools that expedite discoveries and foster meaningful scientific progress. Through this partnership, Premas will contribute Sphere Bio 's high-performance solutions - including their flagship Cyto-Mine® platform and a growing assay portfolio - closer to researchers in South Asia, supported by localized technical expertise and seamless implementation support.
Sphere Bio , formerly known as Sphere Fluidics, is widely recognized for its innovations in single-cell and picodroplet microfluidics. Their technologies enable ultra-high-throughput analysis, sorting, and isolation of individual cells - critical for applications such as antibody discovery, cell line development, and advanced cell therapy research. These platforms are currently used by leading pharma companies And research organizations globally to improve the velocity and precision of biological advancements.
For Premas Life Sciences , this partnership is a natural extension of its mission to democratize access to advanced life science tools. Over the last 18 years, PLS has built a strong legacy of introducing globally benchmarked technologies to India's scientific ecosystem - spanning genomics, proteomics, bioinformatics, and diagnostics. Their ability to not only introduce but also embed technologies through technical training, application support, and long-term scientific partnerships makes them uniquely positioned to amplify the impact of Sphere Bio 's offerings.
"India is entering a new era of biomedical innovation, with increased investments in biosimilars, vaccines, and cell and gene therapies. This collaboration with Sphere Bio allows us to deliver the kind of scientific capabilities that can transform how research is done in this region--faster, more precisely, and with greater reproducibility. With the government's strong push through initiatives like the Bio-E3 policy, PRIP scheme, and its vision for bio foundries, we believe technologies like Sphere Bio 's Cyto-Mine® will play a crucial role in accelerating antibody discovery and cell line development, further strengthening the 'Made in India' biotech ecosystem. We're excited to co-create a future where access to such platforms is not a barrier but a baseline." said Praveen Gupta, Managing Director of Premas Life Sciences .
Sphere Bio Echoing this optimism, Dale Levitzke, CEO of the company, stated, “We view South Asia as a region brimming with significant scientific potential. Our collaboration with Premas transcends mere market entry; it’s focused on achieving lasting effects. Premas contributes extensive local insight, robust technological expertise, and an authentic dedication to fostering innovation. United, our objective is to spark the subsequent generation of advancements in biologics and tailored therapies.” Sphere Bio
"Our partnership with Premas Life Sciences This marks a significant step in our endeavor to bring advanced single-cell technologies within reach across the Asia-Pacific region. Both India and Bangladesh are emerging as dynamic centers for innovation, and we recognize substantial opportunities in equipping local scientists with equipment that adheres to international benchmarks. With their extensive knowledge of the marketplace, robust scientific connections, and history of effectively integrating new tech solutions, Premas stands out as the perfect ally to boost widespread acceptance and achieve meaningful outcomes in this area," stated Jay Manikandan, Vice President of Commercial Operations (APAC). Sphere Bio
This partnership emerges at a crucial juncture, coinciding with the swift transformation of the biotechnology sector in India and Bangladesh. This shift is fueled by governmental support, escalating research and development investments, and an expanding pool of skilled scientists. With the increasing requirement for advanced therapeutic solutions, there is also a heightened necessity for sophisticated, scalable equipment—exactly what is needed. Sphere Bio delivers. Together, Premas and Sphere Bio are building a scientific bridge between global innovation and regional potential. Beyond product access, the partnership offers localized support, training, and tailored solutions aligned with international standards. It sets a new benchmark for how advanced technologies can be effectively introduced and scaled in emerging biotech markets.
(ADVERTORIAL DISCLOSURE: The aforementioned press release has been supplied by India PR Distribution ANI will not bear any responsibility for the content thereof).
Post a Comment for "Premas Life Sciences and Sphere Bio Join Forces to Boost Single-Cell Research in South Asia"